Detalhe da pesquisa
1.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
2.
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Blood
; 134(7): 641-644, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31243043
3.
Clinical and biological characterization of involvement of nasal-associated lymphoid tissues in chronic lymphocytic leukemia.
Am J Hematol
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727145
4.
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Haematologica
; 102(4): 746-754, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126961
5.
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
Am J Hematol
; 97(4): E159-E162, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083778
6.
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Int J Cancer
; 139(8): 1759-63, 2016 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27270786
7.
Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
Br J Haematol
; 191(3): e90-e94, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790071
8.
Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients.
Am J Hematol
; 90(1): E5-8, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25263543
9.
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.
Blood
; 120(2): 356-65, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22613791
10.
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Blood
; 119(22): 5104-10, 2012 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22337714
11.
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Haematologica
; 103(7): e304-e306, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545348
12.
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Haematologica
; 103(8): e356-e359, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519866
13.
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
Am J Hematol
; 93(1): E24-E27, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055105
14.
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
Ann Biol Clin (Paris)
; 81(4): 379-387, 2023 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864443
15.
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.
Cancer Gene Ther
; 30(7): 1018-1028, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36973425
16.
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood Adv
; 7(15): 3936-3945, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37026799
17.
Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters.
Blood
; 116(22): 4588-90, 2010 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-20739656
18.
miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.
Front Immunol
; 13: 983771, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325355
19.
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Blood Adv
; 6(1): 207-211, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34844264
20.
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
Leuk Lymphoma
; 62(13): 3160-3169, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34806520